<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 25,2000
----------------
KING PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0-24425 54-1684963
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
------------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
Effective February 25, 2000, King Pharmaceuticals, Inc., a Tennessee
corporation, acquired Medco Research, Inc. pursuant to a previously announced
merger of the two companies in a tax-free pooling of interests transaction.
Under the terms of the agreement, Medco shareholders will receive .6757 shares
of King common stock in exchange for each share of Medco common stock.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements on Businesses Acquired.
The financial statements required to be filed pursuant to Item 7(a)(1)
are not included with this report. In accordance with Item 7(a)(4), the
Registrant will file such statements no later than May 10, 2000.
(b) Pro Forma Financial Information.
The pro forma financial information required to be filed pursuant to
Item 7(b) is not included with this report. In accordance with Item 7(b)(2),
the Registrant will file such financial information no later than May 10, 2000.
(c) The following exhibits are filed pursuant to Item 601 of Regulation
S-K:
Exhibit
Number Description
------- -----------
99 Press release of King Pharmaceuticals, Inc. dated February 25,
2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: February 25, 2000
By: /s/ Brian G. Shrader
-------------------------------------
Brian G. Shrader
Chief Financial Officer
- 1 -
<PAGE> 1
N E W S R E L E A S E
[KING PHARMACEUTICAL LOGO]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
KING PHARMACEUTICALS COMPLETES
PREVIOUSLY ANNOUNCED MERGER WITH MEDCO RESEARCH
BRISTOL, TENNESSEE, February 25, 2000 - King Pharmaceuticals, Inc. (NASDAQ:KING)
announced today that it has completed the previously announced merger with Medco
Research, Inc. (NYSE:MRE) in a tax-free pooling of interests transaction. Under
the terms of the agreement, Medco shareholders will receive .6757 shares of King
common stock in exchange for each share of Medco common stock.
King, headquartered in Bristol, Tennessee, is a vertically integrated
pharmaceutical company that manufactures, markets, and sells primarily branded
prescription pharmaceutical products. King seeks to capitalize on niche
opportunities in the pharmaceutical industry created by cost containment
initiatives and consolidation among large global pharmaceutical companies.
King's strategy is to acquire branded pharmaceutical products and to increase
their sales by focused promotion and marketing and through product life cycle
management.
# # #
Contact: Kyle P. Macione, Executive Vice President, Investor Relations
- 423-989-8077
EXECUTIVE OFFICES
KING PHARMACEUTICALS -- 501 FIFTH STREET, BRISTOL, TENNESSEE 37620
